Published on: July 10, 2020 at 09:30PM
Condition: Type 2 Diabetes
Interventions: Drug: IBI362; Drug: Placebo; Drug: Dulaglutide
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting
https://ift.tt/3fia7eW
Friday, 10 July 2020
New diabetes clinical trial: Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Nothing happens without a Reason
Make Something out of it.